246 related articles for article (PubMed ID: 12054763)
21. Domain-swapped structure of a mutant of cyanovirin-N.
Botos I; Mori T; Cartner LK; Boyd MR; Wlodawer A
Biochem Biophys Res Commun; 2002 May; 294(1):184-90. PubMed ID: 12054761
[TBL] [Abstract][Full Text] [Related]
22. Solution and crystal molecular dynamics simulation study of m4-cyanovirin-N mutants complexed with di-mannose.
Vorontsov II; Miyashita O
Biophys J; 2009 Nov; 97(9):2532-40. PubMed ID: 19883596
[TBL] [Abstract][Full Text] [Related]
23. [Expression, purification and activity determination of cyanovirin-N].
Chen W; Han B; Qian C; Liu Q; Xiong S
Sheng Wu Gong Cheng Xue Bao; 2010 Apr; 26(4):538-44. PubMed ID: 20575444
[TBL] [Abstract][Full Text] [Related]
24. The role of Glu41 in the binding of dimannose to P51G-m4-CVN.
Ramadugu SK; Li Z; Kashyap HK; Margulis CJ
Biochemistry; 2014 Mar; 53(9):1477-84. PubMed ID: 24524298
[TBL] [Abstract][Full Text] [Related]
25. [New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein].
Mizuochi T; Nakata M
Nihon Rinsho; 1995 Sep; 53(9):2340-9. PubMed ID: 7474402
[TBL] [Abstract][Full Text] [Related]
26. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.
van Die I; van Vliet SJ; Nyame AK; Cummings RD; Bank CM; Appelmelk B; Geijtenbeek TB; van Kooyk Y
Glycobiology; 2003 Jun; 13(6):471-8. PubMed ID: 12626400
[TBL] [Abstract][Full Text] [Related]
27. Rational and computational design of stabilized variants of cyanovirin-N that retain affinity and specificity for glycan ligands.
Patsalo V; Raleigh DP; Green DF
Biochemistry; 2011 Dec; 50(49):10698-712. PubMed ID: 22032696
[TBL] [Abstract][Full Text] [Related]
28. Crystal molecular dynamics simulations to speed up MM/PB(GB)SA evaluation of binding free energies of di-mannose deoxy analogs with P51G-m4-Cyanovirin-N.
Vorontsov II; Miyashita O
J Comput Chem; 2011 Apr; 32(6):1043-53. PubMed ID: 20949512
[TBL] [Abstract][Full Text] [Related]
29. Solution structure of cyanovirin-N, a potent HIV-inactivating protein.
Bewley CA; Gustafson KR; Boyd MR; Covell DG; Bax A; Clore GM; Gronenborn AM
Nat Struct Biol; 1998 Jul; 5(7):571-8. PubMed ID: 9665171
[TBL] [Abstract][Full Text] [Related]
30. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.
Wang LX; Ni J; Singh S; Li H
Chem Biol; 2004 Jan; 11(1):127-34. PubMed ID: 15113002
[TBL] [Abstract][Full Text] [Related]
31. The anti-HIV cyanovirin-N domain is evolutionarily conserved and occurs as a protein module in eukaryotes.
Percudani R; Montanini B; Ottonello S
Proteins; 2005 Sep; 60(4):670-8. PubMed ID: 16003744
[TBL] [Abstract][Full Text] [Related]
32. Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor.
Snyder GA; Ford J; Torabi-Parizi P; Arthos JA; Schuck P; Colonna M; Sun PD
J Virol; 2005 Apr; 79(8):4589-98. PubMed ID: 15795245
[TBL] [Abstract][Full Text] [Related]
33. The antiviral lectin cyanovirin-N: probing multivalency and glycan recognition through experimental and computational approaches.
Woodrum BW; Maxwell JD; Bolia A; Ozkan SB; Ghirlanda G
Biochem Soc Trans; 2013 Oct; 41(5):1170-6. PubMed ID: 24059504
[TBL] [Abstract][Full Text] [Related]
34. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
35. Role of the HIV gp120 conserved domain 5 in processing and viral entry.
Sen J; Jacobs A; Caffrey M
Biochemistry; 2008 Jul; 47(30):7788-95. PubMed ID: 18597484
[TBL] [Abstract][Full Text] [Related]
36. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
37. Solution and crystal structures of a sugar binding site mutant of cyanovirin-N: no evidence of domain swapping.
Matei E; Furey W; Gronenborn AM
Structure; 2008 Aug; 16(8):1183-94. PubMed ID: 18682220
[TBL] [Abstract][Full Text] [Related]
38. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
39. A flexible docking scheme efficiently captures the energetics of glycan-cyanovirin binding.
Bolia A; Woodrum BW; Cereda A; Ruben MA; Wang X; Ozkan SB; Ghirlanda G
Biophys J; 2014 Mar; 106(5):1142-51. PubMed ID: 24606938
[TBL] [Abstract][Full Text] [Related]
40. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
